Trademarkia Logo

Australia

AU$
Trademark Search
DECLARE Dapagliflozin Evaluation of CardiovascuLAR Events
DECLARE Dapagliflozin Evaluation of CardiovascuLAR Events
Removed - Not renewed: Renewal fee not paid

Last updated on 9 Jan 2023

Owner Info

AstraZeneca AB

Vastra Malarehamnen 9

Sodertalje SE-151 85, SWEDEN

Serial Number

1499236 filed on 27 Jun 2012

Correspondent

Spruson & Ferguson

GPO Box 3898,

Sydney, NSW, 2001 AUSTRALIA,

DECLARE Dapagliflozin Evaluation of CardiovascuLAR Events

Classification Information


Class [042]
Medical and scientific research, including conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use

Mark Details


Serial Number

1499236

Registered On

27 Jun 2012

Renewal On

NA

Mark Type

WORD

Priority Claim (Convention Details)


Date

26 Jan 2012

Mark Type

US

Legal History


Show more

Status DateAction Taken
9th Jan 2023IP Right Ceased correspondence sent
9th Jan 2023Status change to Removed/Ceased - Not Renewed
2th Jul 2022Renewal Overdue correspondence sent
27th Apr 2022Renewal Reminder correspondence sent
10th Apr 2014Full Assignment - Subsequent Owner Registered Published
1st Apr 2014Full Assignment
31st Mar 2014Application for Assignment
17th Jan 2013IP Right Registration Published
8th Jan 2013Register Trade Mark
8th Jan 2013Application Status